cancer

UCLA placed highly in 15 of the 16 specialties evaluated by U.S. News and World Report. Only 3 percent of all hospitals were ranked nationally in even one specialty.

UCLA researchers found that a drug, which has shown promise as a treatment for advanced melanoma, could also help regenerate the epidermis.

Researchers have identified mechanisms that determine how the deadliest form of skin cancer can become resistant to immune checkpoint inhibitors, which could lead to the development of new treatments.

Artificial receptors kill cells infected with the virus that causes AIDS, UCLA research finds.

UCLA researchers say the study sheds new light on the way cancer survivors should be monitored during follow-up care.

The study shows the effectiveness of using a vaccine to activate an immune response against advanced brain tumors and it could lead to promising treatments for people with glioblastoma.

A member of the UCLA Jonsson Comprehensive Cancer Center, Demanes will receive the Ulrich Henschke Award in recognition of his dedication and commitment to the field of brachytherapy for more than three decades.

The technique, developed by a team led by UCLA professor Yi Xing, is an innovative way of using biomedical big data to achieve precision medicine.

A team of scientists led by doctors at UCLA demonstrated that a modified virus has been shown to extend the lives of people with recurrent gliobastoma.

Scientists found that a protein called cystatin E/M can inhibit cellular inflammation, which is a major contributor to the growth of the disease; the discovery could lead to the development of new treatments.

Chaplain Michael Eselun of the Simms/Mann UCLA Center for Integrative Oncology discusses the power in our stories to make spiritual sense of our lives.

A member of the UCLA Jonsson Comprehensive Cancer Center, Lo has been awarded $900,000 by the Melanoma Research Alliance Foundation.

A UCLA study shows that the drug pembrolizumab also has fewer side effects than traditional treatments.

Ribas, who is working to create a cancer-fighting immune system, received the Rosenthal Family Foundation Award from the American Association for Cancer Research.

An earlier study had suggested that a class of drugs called anthracyclines might increase the risk for neuropsychological issues and cognitive difficulties.

Eventually, doctors might be able to analyze the levels and types of patients’ intestinal bacteria and then prescribe probiotics to bolster the amount of bacteria with anti-inflammatory properties.

The device combines two components invented at UCLA: a photonic time stretch microscope and a deep learning computer program that identifies cancer cells with over 95 percent accuracy.

The new technique uses penny-sized microfluidic chips that are equipped with minuscule DNA “bar codes,” which are no bigger than a single cell.

Already a leader in the field, UCLA will collaborate with five of the nation’s other top cancer centers in the Parker Institute for Cancer Immunotherapy.

The new technique assesses how changes in a person’s immune response can help predict the effectiveness of a new therapy in people who have the most common and deadly type of brain cancer.

The new technique can accurately identify a person’s optimal drug and dose combinations throughout an entire course of treatment, without complex, time-consuming genetic analysis.

The researchers found that an experimental drug called CD532, which changes the structure of a key protein, reduced the size of tumors in mice by 80 percent.

Funding from the California Institute for Regenerative Medicine will support work to genetically engineer immune cells to fight cancer.

Discovery is an important step in the effort to better understand and treat aggressive childhood leukemia.

Mesoporous silica nanoparticles deliver the drug directly to the tumor instead of having it spread through the bloodstream.